- Home
- FWRG vs LQDA Comparison
FWRG vs LQDA Comparison
Compare FWRG & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- LQDA
- Stock Information
- Founded
- FWRG 1983
- LQDA 2004
- Country
- FWRG United States
- LQDA United States
- Employees
- FWRG N/A
- LQDA N/A
- Industry
- FWRG Restaurants
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- LQDA Health Care
- Exchange
- FWRG Nasdaq
- LQDA Nasdaq
- Market Cap
- FWRG 1.2B
- LQDA 1.3B
- IPO Year
- FWRG 2021
- LQDA 2018
- Fundamental
- Price
- FWRG $20.27
- LQDA $16.12
- Analyst Decision
- FWRG Strong Buy
- LQDA Strong Buy
- Analyst Count
- FWRG 10
- LQDA 7
- Target Price
- FWRG $23.50
- LQDA $26.67
- AVG Volume (30 Days)
- FWRG 514.0K
- LQDA 746.6K
- Earning Date
- FWRG 03-11-2025
- LQDA 03-12-2025
- Dividend Yield
- FWRG N/A
- LQDA N/A
- EPS Growth
- FWRG N/A
- LQDA N/A
- EPS
- FWRG 0.33
- LQDA N/A
- Revenue
- FWRG $997,252,000.00
- LQDA $15,610,000.00
- Revenue This Year
- FWRG $16.20
- LQDA N/A
- Revenue Next Year
- FWRG $15.83
- LQDA $206.64
- P/E Ratio
- FWRG $61.21
- LQDA N/A
- Revenue Growth
- FWRG 19.77
- LQDA N/A
- 52 Week Low
- FWRG $12.90
- LQDA $8.26
- 52 Week High
- FWRG $25.98
- LQDA $16.99
- Technical
- Relative Strength Index (RSI)
- FWRG 48.91
- LQDA 68.76
- Support Level
- FWRG $19.46
- LQDA $16.10
- Resistance Level
- FWRG $22.71
- LQDA $16.81
- Average True Range (ATR)
- FWRG 0.96
- LQDA 0.56
- MACD
- FWRG -0.09
- LQDA -0.05
- Stochastic Oscillator
- FWRG 24.92
- LQDA 76.20
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.